Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-02-15
2005-02-15
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S265100
Reexamination Certificate
active
06855316
ABSTRACT:
Compositions and methods are provided for the induction of a protective immunize response in primates against lethal challenge ofPlasmodium.
REFERENCES:
patent: 4745051 (1988-05-01), Smith et al.
patent: 6270800 (2001-08-01), Speaker et al.
patent: 0 329 257 (1989-08-01), None
Soltysik et al. (Vaccine 1995 vol. 13(15) pp. 1403-1410).*
Smilek, D. et al., “A single amino acid change in myelin basic protein peptide confers the capacity to prevent rather than induce EAE”, PNAS 88:9633-37 (1991).
Cheung et al. “Immunization with synthetic peptides of aPlasmodium falciparumsurface antigen induces antimerozoite antibodies,” Proc. Natl. Acad. Sci. USA 83:8328 (1986).
Hall et al., “Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria,” Nature 311:379 (1984).
Herrera et al. “Immunization of Aotus monkeys withPlasmodium falciparumblood-stage recombinant proteins,” Proc. Natl. Acad. Sci. USA 87:4017 (1990).
Herrera et al. “Conserved Polypeptides ofPlasmodium falciparumas Malaria Vaccine Candidates?”, Acta Leidensia, 60(1): 107-110 (1991).
Holder et al. “Immunization against blood-stage rodent malaria using purified parasite antigens,” Nature 294:361 (1981).
Hui et al., “Serum from Pf195 protected Aotus Monkeys InhibitPlasmodium falciparumgrowth in Vitro,” Exp. Parasitol. 64:519 (1987).
Knapp et al. “A histidin alanine rich recombinant antigen protects aotus monkeys fromP. falcipariuminfection,” Behring Inst. Mitt. 82:349 (1988).
Lew et al. “A protective monoclonal antibody recognizes a linear epitope in the precursor to the major merozoite antigens ofPlasmodium chabaudi adami,” Proc. Natl. Acad. Sci. USA 86:3768 (1989).
Majarian et al. “Passive Immunization against Murine Malaria with an IgG3 Monoclonal Antibody,” J. Immunol. 132:3131 (1984).
Patarroyo et al. “A synthetic vaccine protects humans against challenge with asexual blood stages ofPlasmodium falciparummalaria,” Nature 332:158 (1988).
Patarroyo et al. “Protective Synthetic Peptides against ExperimentalPlasmodium falciparum-induced Malaria,” Vaccines 87 (Brown, Chanock, Lerner, ed.) Cold Spring Harbor Laboratory Press, CSH, NY. 117-124 (1987).
Patarroyo et al. “Induction of protective immunity against experimental infection with malaria using synthetic peptides,” Nature 328:629 (1987).
Perrin et al. “Antimalarial Immunity in Saimiri Monkeys,” J. Exp. Med. 160:441 (1984).
Ruebush et al.. “Immunization of Owl Monkeys with a Combination ofPlasmodium falciparumAsexual Blood-Stage Synthetic Peptide Antigens,” Am. J. Trop. Med. Hyg. 43:355-366 (1990).
Rodriguez et al. Studies In Owl Monkeys Leading to the Development of a Synthetic Vaccine Against the Asexual Blood Stages ofPlasmodium falciparum, Am. J. Trop. Med. Hyg. 43:339 (1990).
Siddiqui et al. “Merozoite surface coat precursor protein completely protects Aotus monkeys againstPlasmodium falciparummalaria,” 1987. Proc. Natl. Acad. Sci. USA 84:3014.
Odink KG. et al., “Expression of cloned cDNA for a major surface antigen ofPlasmodium falciparummerozoite,” FEBS Lett. (1984) 108-12.
Murphy et al., “Expression of hybrid malaria anitgens in insect cells and their engineering for correct folding and secretion,” Parasitology, 100:177-183 (100).
Holder et al., “A hybrid gene to express protein epitopes from both sporozoite and merozoite surface antigens oflasmodium falciparum,” Parasitology, 97:373-382 (1988).
Schwarz et al, “Structural Diversity of the Major Surface Antigen ofPlasmodium falciparumMerozoites,” Molecular and Cellular Biology, 6(3):964-968 (1986).
Holder et al., “Primary Structure of the Precursor to the three major surface antigens ofPlasmodium falciparummerozoite,” Nature, 317:270-273 (1985).
Holder et al., “Processing of the precursor to the major merozoite surface antigens ofPlasmodium falciparum,” Parasilogy, 94:199-208 (1987).
Tanabe, et al., “Allelic Dimorphism in a Surface Antigen Gene of the Malaria ParasitePlasmodium falciparum,” J. Mol. Biol., 195:273-287 (1987).
Holder et al., “Immunization againstPlasmodium falciparumwith recombinant polypeptides produced inEscherichia coli,” Parastic Immunology, 10:607-617 (1988).
Chang, et al., “Plasmodium falciparum:Gene Structure and Hydropathy Profile of the Major Merozoite Surface Antigen (gp195) of the Uganda-Palo Alto Isolate”Experimental Parasitology,67: 1-11 (1988).
Hui, et al., “Roles of Conserved and Allelic Regions of the Major Merozoite Surface Protein (gp195) in Immunity againstPlasmodium falciparum” Infection and Immunity60:1422-1433 (1992).
Hui, et al. “Induction of Antibodies to thePlasmodium falciparumMerozoite Surface Protein-1 (MSP1) by Cross-Priming with Heterologous MSPs”J. of Immunology,153: 1195-1201 (1994).
Nishimura, T.A.T., “Distribution of MSP-1 Dimorphism in Papua New Guinea and the Importance of BVp42 Dimorphism in Antibody Recognition”, Master of Science in Microbiology Thesis, University of Hawaii (Dec. 1999).
Chang Sandra P.
Gosnell William L.
Kramer Kenton J.
Nishimura Tani
Dorsey & Whitney LLP
Lorenz Todd A.
Navarro Mark
Trecartin Richard F.
University of Hawai'i
LandOfFree
Baculovirus produced Plasmodium falciparum vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Baculovirus produced Plasmodium falciparum vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Baculovirus produced Plasmodium falciparum vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3481079